Mike Aylott
Overview
Explore the profile of Mike Aylott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Milliken P, Aylott M, Edmunds N, Engle S, Ewart L, Fleurance R, et al.
Toxicol Sci
. 2020 Apr;
176(1):224-235.
PMID: 32298455
Integrating nonclinical in vitro, in silico, and in vivo datasets holistically can improve hazard characterization and risk assessment. In pharmaceutical development, cardiovascular liabilities are a leading cause of compound attrition....
2.
Rowley T, Peters S, Aylott M, Griffin R, Davies N, Healy L, et al.
Commun Biol
. 2018 Oct;
1:146.
PMID: 30272022
Autoantibody-mediated diseases are currently treated with intravenous immunoglobulin, which is thought to act in part via blockade of Fc gamma receptors, thereby inhibiting autoantibody effector functions and subsequent pathology. We...
3.
Ewart L, Aylott M, Deurinck M, Engwall M, Gallacher D, Geys H, et al.
Toxicol Sci
. 2014 Sep;
142(2):427-35.
PMID: 25246669
It is widely accepted that more needs to be done to bring new, safe, and efficacious drugs to the market. Cardiovascular toxicity detected both in early drug discovery as well...
4.
Stegemann S, Connolly P, Matthews W, Barnett R, Aylott M, Schrooten K, et al.
AAPS PharmSciTech
. 2014 Feb;
15(3):542-9.
PMID: 24526655
Understanding the product and process variable on the final product performance is an essential part of the quality-by-design (QbD) principles in pharmaceutical development. The hard capsule is an established pharmaceutical...
5.
Harris K, Aylott M, Cui Y, Louttit J, McMahon N, Sridhar A
Toxicol Sci
. 2013 May;
134(2):412-26.
PMID: 23690542
Human-induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) are a potential source to develop assays for predictive electrophysiological safety screening. Published studies show that the relevant physiology and pharmacology exist but does...
6.
Reus A, Usta M, Kenny J, Clements P, Pruimboom-Brees I, Aylott M, et al.
Mutagenesis
. 2012 Sep;
27(6):721-9.
PMID: 22935223
An in vivo photomicronucleus test (MNT) using rat skin, the target organ for photoirritancy and carcinogenicity, was recently described. The assay was evaluated using fluoroquinolone (FQ) antibiotics with varying degrees...
7.
Lynch A, Giddings A, Custer L, Gleason C, Henwood A, Aylott M, et al.
Environ Mol Mutagen
. 2011 Dec;
52(9):699-710.
PMID: 22167885
N-methyl-N-nitrosourea (MNU) was evaluated in the in vivo Pig-a mutation assay as part of an International Collaborative Trial to investigate laboratory reproducibility, 28-day study integration, and comparative analysis with micronucleus...
8.
Jarvis P, Saul J, Aylott M, Bate S, Geys H, Sherington J
Pharm Stat
. 2011 Dec;
10(6):477-84.
PMID: 22140058
The Statisticians in the Pharmaceutical Industry Toxicology Special Interest Group has collated and compared statistical analysis methods for a number of toxicology study types including general toxicology, genetic toxicology, safety...
9.
Bright J, Aylott M, Bate S, Geys H, Jarvis P, Saul J, et al.
Pharm Stat
. 2011 Dec;
10(6):485-93.
PMID: 22127874
In 2010, the Statisticians in the Pharmaceutical Industry (PSI) Toxicology Special Interest Group met to discuss the design and analysis of the Comet assay. The Comet assay is one potential...
10.
Aylott M, Bate S, Collins S, Jarvis P, Saul J
Pharm Stat
. 2010 Oct;
10(3):236-49.
PMID: 20967892
In 2008, the PSI Toxicology Special Interest Group met to discuss the design and analysis of dog telemetry studies. The dog telemetry study is one component of the integrated cardiovascular...